SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GZTC
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Steve Push who wrote (221)9/7/1997 11:47:00 AM
From: Meridian   of 752
 
Steve,

Is there any pharmacokenitic difference between the ATIII which is currently on the market and that which is being produced transgenically? It seems to me that the only significant difference is the production method. If so, could we infer that the phase III trial stands a reasonably good chance of being successful (I know you can't comment on that one, but I thought I'd throw it out for the rest of the group)?

Also, if GZTC can prove bioequivelance for other proteins will they have to go through all of the trials or just a phase II/III trial?

Thanks for any input you can provide.

Brian
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News